Increased APP (amyloid precursor protein) processing causes β-amyloid (Aβ) accumulation in autosomal dominant Alzheimer's disease (AD), but it is unclear if it also affects sporadic Aβ accumulation. We tested healthy controls and patients with mild cognitive symptoms (N=331) in the BioFINDER study, using cerebrospinal fluid (CSF) Aβ40 as a surrogate for amyloidogenic APP processing. We find that levels of brain Aβ fibrils (measured by 18F-flutemetamol PET) are independently associated with high CSF Aβ40 (P<0.001) and APOE ɛ4 (P<0.001). The association between CSF Aβ40 and brain Aβ is stronger in APOE ɛ4-negative than in positive people (P=0.0080). The results are similar for CSF Aβ38 and for a combination of CSF Aβ38 and CSF Aβ40. In conclu...
The devastating symptoms of Alzheimer's disease result from a progressive regional neurodegenerative...
Background: APOE ε4’s role as a modulator of the relationship between soluble plasma beta-amyloid (A...
Abstract: Mismatch between CSF and PET amyloid-β biomarkers occurs in up to ≈20% of preclinical/pro...
Increased APP (amyloid precursor protein) processing causes β-amyloid (Aβ) accumulation in autosomal...
Amyloid (Aβ) pathology is the earliest detectable pathophysiological event along the Alzheimer's con...
Misfolding and aggregation of amyloid β (Aβ) are key features of Alzheimer's disease (AD) pathogenes...
Aggregation of amyloid β into plaques in the brain is one of the earliest pathological events in Alz...
AbstractMisfolding and aggregation of amyloid β (Aβ) are key features of Alzheimer's disease (AD) pa...
The association between cerebrospinal fluid (CSF) amyloid beta (Aβ) Aβ38 or Aβ40 and brain grey- and...
The cerebral deposition of Aβ42, a neurotoxic proteolytic derivate of amyloid precursor protein (APP...
BACKGROUND: The human APOE gene, which codes for apolipoprotein E (apoE), has three major polymorphi...
BACKGROUND: One of the key pathological hallmarks of Alzheimer disease (AD) is the accumulation of t...
Background: To assess the effects of apolipoprotein E (ApoE) ε4 genotype on amyloid-β (Aβ) and tau b...
Altres ajuts: This publication is part of the AETIONOMY project (Organising Mechanistic Knowledge ab...
BackgroundApolipoprotein E ε4 (ApoE4) has been associated with an increased risk of Alzheimer's dise...
The devastating symptoms of Alzheimer's disease result from a progressive regional neurodegenerative...
Background: APOE ε4’s role as a modulator of the relationship between soluble plasma beta-amyloid (A...
Abstract: Mismatch between CSF and PET amyloid-β biomarkers occurs in up to ≈20% of preclinical/pro...
Increased APP (amyloid precursor protein) processing causes β-amyloid (Aβ) accumulation in autosomal...
Amyloid (Aβ) pathology is the earliest detectable pathophysiological event along the Alzheimer's con...
Misfolding and aggregation of amyloid β (Aβ) are key features of Alzheimer's disease (AD) pathogenes...
Aggregation of amyloid β into plaques in the brain is one of the earliest pathological events in Alz...
AbstractMisfolding and aggregation of amyloid β (Aβ) are key features of Alzheimer's disease (AD) pa...
The association between cerebrospinal fluid (CSF) amyloid beta (Aβ) Aβ38 or Aβ40 and brain grey- and...
The cerebral deposition of Aβ42, a neurotoxic proteolytic derivate of amyloid precursor protein (APP...
BACKGROUND: The human APOE gene, which codes for apolipoprotein E (apoE), has three major polymorphi...
BACKGROUND: One of the key pathological hallmarks of Alzheimer disease (AD) is the accumulation of t...
Background: To assess the effects of apolipoprotein E (ApoE) ε4 genotype on amyloid-β (Aβ) and tau b...
Altres ajuts: This publication is part of the AETIONOMY project (Organising Mechanistic Knowledge ab...
BackgroundApolipoprotein E ε4 (ApoE4) has been associated with an increased risk of Alzheimer's dise...
The devastating symptoms of Alzheimer's disease result from a progressive regional neurodegenerative...
Background: APOE ε4’s role as a modulator of the relationship between soluble plasma beta-amyloid (A...
Abstract: Mismatch between CSF and PET amyloid-β biomarkers occurs in up to ≈20% of preclinical/pro...